With Over 50% Share Cleavable Linker Leading from the Front in Antibody Drug Conjugates Contract Market, States Fact.MR
Antibody-Drug Conjugates (ADC) contract manufacturing is putting in place systems to deal with difficult supply chains, as well as infrastructure and processes to ensure security, quality, and efficiency. As a result of the planned growth in ADC demand, the contract manufacturing market for ADCs is expected to grow significantly in the future years, comments a Fact.MR analyst.
Fact.MR – A Market Research and Competitive Intelligence Provider: The Antibody Drug Conjugates Contract industry revenues were valued at US$ 8.1Bn in 2021 and have been predicted to grow at a CAGR of 15.5% from 2022-2032, according to a recently published Fact.MR report. By the end of 2032, the market is expected to cross the value of US$ 39 Bn. During the historical period of 2015-2021, the market segment for cleavable linkers expanded at a CAGR of 12.6 %, and it is predicted to increase at a CAGR of 17.2 percent during the forecasted period of 2022-2032.
Antibody-drug conjugates are a type of biopharmaceutical used to treat cancer that consists of an antibody that targets a tumor antigen specifically a cytotoxic substance linked by a chemical linker. They're designed to allow the cytotoxic substance to be precisely targeted to kill tumor cells while causing minimal damage to healthy tissue. Because ADCs are a new class of biopharmaceuticals, their development necessitates are both chemical and biological expertise. Technical expertise in conjugation and linker development, as well as robust platforms, are provided by contract manufacturing companies.
Key Takeaways from the Market Study
· Antibody Drug Conjugates Contract market is expected to cross the market value of US$ 9.2 Bn by 2022.
· The Asia Pacific is anticipated to be the most lucrative region in terms of growth.
· Myeloma to be the most successful condition type with the expected CAGR of 17% CAGR in the next 10 years.
· US with US$ 7.3 Bn anticipated market value in 2032 to be the most promising revenue generating country.
Competitive Landscape
· A number of regional and global players operate in this market. These companies compete based on the innovation of their products, their quality, their brand reputation, and their market presence in order to sell their products through various industries. A variety of strategies are being employed by companies to remain competitive.
· In January 2022, Merck and ID Pharma Signed a Memorandum of Understanding to Accelerate Gene Therapy Development and Manufacturing.
· In December 2021, Merck announced that it has joined forces with Innovative Biotech to support the establishment of Nigeria's first vaccine manufacturing facility.
· In July 2021, Recipharm signed a Memorandum of Understanding (MOU) for the fill-finish of vaccines and biotherapeutics in Morocco.
Full Report https://www.factmr.com/report/antibody-drug-conjugates-contract-market
Contact Us:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com
Website: https://www.factmr.com
